Back to Article
Clinical characteristics of COVID-19 patients who received ventilator management during the omicron variant period in a tertiary hospital in Japan
World Journal of Clinical Medicine Research
| Vol 5, Issue 1
Table 1. Clinicalcharacteristics of 11 adult COVID-19 received with ventilator management
| Age | M/F | Ward | Underlying diseases | Vaccine | Ag titer | Bacteria | Antivirals | Antibiotics | Steroid | NAb | ECMO | Survive/Death | |
| 1 | 72 | M | ER | COPD, | Unknown | 190 | Hi | RDV | MEPM | Dex | STV | None | S |
| 2 | 76 | M | ER | COPD, | Unknown | 42.7 | Hi, Ef | RDV | LSFX | Dex | None | None | S |
| 3 | 79 | M | SCU | Parkinson Dis | Unknown | 670 | None | RDV | SBT/ABPC | Dex | None | None | Death |
| 4 | 81 | M | ER | Nursing home | 5 | 3457 | None | RDV | SBT/ABPC | Dex | STV | None | S |
| 5 | 76 | M | ER | CKD | 6 | 2916 | MSSA, Kp | RDV | MEPM | Dex | STV | None | S |
| 6 | 72 | M | ER | ALS | 6 | 20912 | E coli | RDV | MEPM | Dex | STV | None | S |
| 7 | 55 | M | ER | Brain tumor | 3 | 15,4 | MSSA | RDV | TAZ/PIP | Dex | None | Positive | S |
| 8 | 85 | M | ER | CHD | None | 4809 | None | RDV | SBT/ABPC | Dex | None | None | Death |
| 9 | 51 | F | ER | Conversion | Unknown | 19.2 | MRSA | RDV | LZD | Dex | STV | Positive | S |
| 10 | 54 | M | ER | None | None | 28.3 | None | RDV | TAZ/PIPC | Dex | None | Positive | S |
| Age | M/F | Ward | Underlying diseases | Vaccine | Ag titer | Bacteria | Antivirals | Antibiotics | Steroid | NAb | ECMO | Survive/Death | |
Abbreviations: M/F: male/female, ER: emergency department, SCU: stroke intensive care unit, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, ALS: amyotrophic lateral sclerosis, CHD: chronic heart disease, HD: hemodyalysis, Hi: Haemophilus influenzae, Ef: enterococcus faecalis, MSSA: methicillin susceptible Staphylococcus aureus, Kp: Klebsiella pneumoniae, MRSA: methicillin resistance Staphylococcus aureus, RDV: remdesivir, MEPM: meropenem, LVFX: levofloxacin, SBT/ABPC: sulbactam/ampicillin, TAZ/PIPC: tazobactam/piperacillin, LZD: linezolid, CFPM: cefepime, Dex: dexamethasone, N ab: neutralizing antibody, STV: sotrovimab, ECMO: extracorporeal membrane oxygenation, S: survive